open access
Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option
- Department of Neurology, Medical University of Warsaw, 8 Kondratowicza str, 03-242 Warsaw, Poland
- Department of Bioethics, Medical University of Warsaw, Zwirki i Wigury 63, Warsaw, Poland
open access
Abstract
Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia, bipolar disorder or depression with psychotic ideation. However, recently a number of new possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS). In two randomized, double-blind, placebo-controlled studies in children and adolescents with GTS has been confirmed the efficacy of aripiprazole in tic reduction. In comparison to other neuroleptics, aripiprazole seems to be similarly effective. What is more, the number and profile of possible adverse effects is also favorable. As a consequence, aripiprazole had been registered by Food and Drug Administration (FDA) for the treatment of tics and represents new therapeutic option in treatment of GTS.
Abstract
Aripiprazole is a dopamine D2- and serotonin 5-hydroxytryptamine (5-HT)1A receptor partial agonist and 5-HT2A receptor antagonist primarily used for the treatment of schizophrenia, bipolar disorder or depression with psychotic ideation. However, recently a number of new possible indications have been suggested, among them Gilles de la Tourette syndrome (GTS). In two randomized, double-blind, placebo-controlled studies in children and adolescents with GTS has been confirmed the efficacy of aripiprazole in tic reduction. In comparison to other neuroleptics, aripiprazole seems to be similarly effective. What is more, the number and profile of possible adverse effects is also favorable. As a consequence, aripiprazole had been registered by Food and Drug Administration (FDA) for the treatment of tics and represents new therapeutic option in treatment of GTS.
Keywords
Gilles de la Tourette syndrome, Aripiprazole, Randomized double-blind placebo-controlled study
Title
Aripiprazole in treatment of Gilles de la Tourette syndrome – New therapeutic option
Journal
Neurologia i Neurochirurgia Polska
Issue
Article type
Review Article
Pages
84-87
Published online
2017-11-09
Page views
803
Article views/downloads
1418
DOI
10.1016/j.pjnns.2017.10.015
Bibliographic record
Neurol Neurochir Pol 2018;52(1):84-87.
Keywords
Gilles de la Tourette syndrome
Aripiprazole
Randomized double-blind placebo-controlled study
Authors
Piotr Janik
Natalia Szejko